These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25667198)

  • 21. Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.
    Gold DT; Bonnick SL; Amonkar MM; Kamel HK; Agarwal S; Zaidi M
    Gend Med; 2008 Dec; 5(4):374-84. PubMed ID: 19108810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucocorticoid-induced osteoporosis.
    Berris KK; Repp AL; Kleerekoper M
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):446-50. PubMed ID: 17982350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits and risks of bisphosphonate therapy for osteoporosis.
    Khosla S; Bilezikian JP; Dempster DW; Lewiecki EM; Miller PD; Neer RM; Recker RR; Shane E; Shoback D; Potts JT
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2272-82. PubMed ID: 22523337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
    Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
    Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonates and their influence on fracture healing: a systematic review.
    Molvik H; Khan W
    Osteoporos Int; 2015 Apr; 26(4):1251-60. PubMed ID: 25572046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fracture prevention in postmenopausal osteoporosis: a review of treatment options.
    McCarus DC
    Obstet Gynecol Surv; 2006 Jan; 61(1):39-50. PubMed ID: 16359568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonate use in patients undergoing dialysis.
    Vouri SM; Blaszczyk AT
    Consult Pharm; 2013 Nov; 28(11):738-41. PubMed ID: 24217193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates for osteoporosis--where do we go from here?
    Whitaker M; Guo J; Kehoe T; Benson G
    N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
    [No Abstract]   [Full Text] [Related]  

  • 35. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
    Aspray TJ; Francis RM
    Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fracture risk and treatment in chronic kidney disease.
    Connelly K; Collister D; Tangri N
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):221-225. PubMed ID: 29547405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.